Status:
UNKNOWN
Study of the Practice of Debiri in France
Lead Sponsor:
Federation Francophone de Cancerologie Digestive
Conditions:
Colorectal Adenocarcinoma
Hepatic Metastases
Eligibility:
All Genders
18-130 years
Brief Summary
In order to extract the profiles of patients receiving DEBIRI treatment at best, the investigators proposed the establishment of a national prospective cohort to collect information on the greatest nu...
Detailed Description
Colorectal cancer (CRC) is the third most common cancer in men and the second in women (1.23 million cases in 2008, 608700 deaths) 40 to 50% of patients developed hepatic, synchronous or metachronous ...
Eligibility Criteria
Inclusion
- Patients aged 18 years and over
- Histologically proven colorectal adenocarcinoma
- Synchronous or metachronous hepatic metastases
- No significant extrahepatic disease
- Indication of treatment by DEBIRI retained
- Patient who received the information note
Exclusion
- Patients who started treatment with DEBIRI before 2015
- Patients who for psychological, social, family or geographic reasons could not be monitored regularly.
Key Trial Info
Start Date :
February 3 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 15 2022
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT03369041
Start Date
February 3 2016
End Date
October 15 2022
Last Update
August 19 2022
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de Blois
Blois, France
2
Avicenne
Bobigny, France
3
CHU Estaing
Clermont-Ferrand, France
4
Clinique des Cèdres
Cornebarrieu, France